Treatment of the myeloid/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor

Ann Oncol. 2018 Aug 1;29(8):1880-1882. doi: 10.1093/annonc/mdy173.

Authors

S Verstovsek¹, V Subbiah², L Masarova³, C Cameron Yin⁴, G Tang⁴, T Manshouri³, E Asatiani⁵, N G Daver³

Affiliations

¹ Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: sverstov@mdanderson.org.
² Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA.
³ Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA.
⁴ Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA.
⁵ Department of Incyte Corporation, Wilmington, USA.

No abstract available

Publication types

Case Reports
Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Administration, Oral
Eosinophilia / drug therapy*
Eosinophilia / genetics
Humans
Lymphoma / drug therapy*
Lymphoma / genetics
Male
Middle Aged
Myeloproliferative Disorders / drug therapy*
Myeloproliferative Disorders / genetics
Oncogene Proteins, Fusion / genetics*
Protein Kinase Inhibitors / pharmacology
Protein Kinase Inhibitors / therapeutic use*
Receptor, Fibroblast Growth Factor, Type 1 / antagonists & inhibitors*
Receptor, Fibroblast Growth Factor, Type 1 / genetics*
Treatment Outcome

Substances

Oncogene Proteins, Fusion
Protein Kinase Inhibitors
FGFR1 protein, human
Receptor, Fibroblast Growth Factor, Type 1
CEP110-FGFR1 fusion protein, human

Supplementary concepts

Myeloproliferative Disorder, Chronic, with Eosinophilia